Lifesci Capital Begins Coverage on Revolution Medicines (NASDAQ:RVMD)

Key Points

• Analysts at Lifesci Capital have initiated coverage of Revolution Medicines (RVMD), giving the stock an "outperform" rating and a price target of $80.00, suggesting a potential upside of 120.26% from its previous close.
• The stock currently has an average rating of "Buy" from thirteen research analysts, with a consensus target price of $69.54 as of recent evaluations.
• Revolution Medicines reported a quarterly loss of ($1.31) earnings per share, missing the consensus estimate, while forecasting a projected loss of ($3.49) EPS for the current fiscal year.

Lifesci Capital started coverage on shares of Revolution Medicines (NASDAQ:RVMD - Free Report) in a research report released on Monday, Marketbeat reports. The brokerage issued an outperform rating and a $80.00 target price on the stock. Lifesci Capital also issued estimates for Revolution Medicines' Q3 2025 earnings at ($1.32) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($5.11) EPS, Q1 2026 earnings at ($1.41) EPS, Q2 2026 earnings at ($1.44) EPS, Q3 2026 earnings at ($1.51) EPS, Q4 2026 earnings at ($1.49) EPS and FY2026 earnings at ($5.93) EPS.

A number of other equities analysts also recently commented on RVMD. Oppenheimer lifted their price objective on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Guggenheim reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Revolution Medicines in a report on Wednesday, June 25th. Needham & Company LLC decreased their price objective on shares of Revolution Medicines from $57.00 to $56.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Wedbush reaffirmed an "outperform" rating and issued a $73.00 price objective (up previously from $67.00) on shares of Revolution Medicines in a report on Tuesday, June 24th. Finally, The Goldman Sachs Group began coverage on shares of Revolution Medicines in a report on Tuesday, July 15th. They issued a "buy" rating and a $65.00 price objective for the company. Thirteen analysts have rated the stock with a Buy rating, According to MarketBeat.com, Revolution Medicines currently has a consensus rating of "Buy" and a consensus target price of $69.92.

Revolution Medicines Stock Performance

Revolution Medicines stock traded up $0.53 during mid-day trading on Monday, reaching $37.01. The company's stock had a trading volume of 1,091,784 shares, compared to its average volume of 1,900,156. The firm has a market cap of $6.92 billion, a price-to-earnings ratio of -8.22 and a beta of 1.16. The business has a 50 day moving average price of $37.48 and a 200-day moving average price of $38.39. The company has a current ratio of 11.79, a quick ratio of 11.79 and a debt-to-equity ratio of 0.13. Revolution Medicines has a twelve month low of $29.17 and a twelve month high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). The business's quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.81) EPS. Sell-side analysts predict that Revolution Medicines will post -3.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Revolution Medicines

Several hedge funds and other institutional investors have recently modified their holdings of the company. Marex Group plc acquired a new position in shares of Revolution Medicines during the second quarter valued at $284,000. Hudson Bay Capital Management LP acquired a new stake in Revolution Medicines in the second quarter worth about $1,124,000. CANADA LIFE ASSURANCE Co lifted its holdings in Revolution Medicines by 14.4% in the second quarter. CANADA LIFE ASSURANCE Co now owns 34,766 shares of the company's stock worth $1,282,000 after purchasing an additional 4,386 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Revolution Medicines by 592.2% in the second quarter. Tower Research Capital LLC TRC now owns 71,534 shares of the company's stock worth $2,632,000 after purchasing an additional 61,199 shares during the period. Finally, E Fund Management Co. Ltd. lifted its holdings in Revolution Medicines by 11.8% in the second quarter. E Fund Management Co. Ltd. now owns 17,075 shares of the company's stock worth $628,000 after purchasing an additional 1,802 shares during the period. Institutional investors and hedge funds own 94.34% of the company's stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.